OM - NASDAQ
Outset Medical, Inc.
$4.60
-6.3%Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
At a Glance
Live SnapshotOutset Medical, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Outset Medical, Inc. Income Statement
OM • NASDAQ
| Outset Medical, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
119.5M | 113.7M | 130.4M | 115.4M | 102.6M | 49.9M | 15.1M | 2M | |
GROSS PROFIT | ||||||||
(72.7M) | (75.1M) | (101.4M) | (97.5M) | (95M) | (63M) | (32.9M) | (8.1M) | |
46.8M | 38.6M | 29M | 17.8M | 7.6M | -13M | -17.8M | -6.1M | |
OPERATING INCOME | ||||||||
(113.5M) | (151.9M) | (198.8M) | (178.9M) | (138.1M) | (104.4M) | (52.5M) | (40.4M) | |
(92.2M) | (113.5M) | (141.5M) | (130M) | (101.4M) | (75.6M) | (29.2M) | (17.5M) | |
(21.2M) | (38.4M) | (57.3M) | (48.9M) | (36.7M) | (28.9M) | (23.3M) | (22.9M) | |
-66.7M | -113.4M | -169.8M | -161M | -130.5M | -117.5M | -70.3M | -46.6M | |
PRE-TAX INCOME | ||||||||
(14M) | (23.9M) | (12.7M) | (3.6M) | (1.7M) | (2.9M) | (4.3M) | (4.6M) | |
-6.5M | -14.1M | -2.5M | -275K | -1.2M | -2.4M | -1.8M | -2.9M | |
-14.2M | -14.1M | -2.5M | -1.6M | -1.2M | -4M | 2M | -3.2M | |
-80.9M | -127.5M | -172.3M | -162.7M | -131.7M | -121.5M | -68.3M | -49.8M | |
NET INCOME | ||||||||
(718K) | (491K) | (523K) | (295K) | (199K) | (0.0) | (20K) | (25K) | |
-81.7M | -128M | -172.8M | -163M | -131.9M | -120.7M | -68.3M | -49.8M |
SEC Filings
OM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 |
Related Guides
Continue your OM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.